Conflict of interest: Nothing to report.
International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens†
Article first published online: 3 DEC 2010
Copyright © 2010 Wiley-Liss, Inc.
American Journal of Hematology
Volume 86, Issue 1, pages 96–98, January 2011
How to Cite
Thapaliya, P., Tefferi, A., Pardanani, A., Steensma, D. P., Camoriano, J., Wu, W., Geyer, S. and Mesa, R. A. (2011), International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens. Am. J. Hematol., 86: 96–98. doi: 10.1002/ajh.21892
- Issue published online: 17 DEC 2010
- Article first published online: 3 DEC 2010
- Accepted manuscript online: 30 SEP 2010 07:17PM EST
We have previously reported the benefits of combination therapy with thalidomide and prednisone for the improvement of cytopenias and splenomegaly for patients with myelofibrosis (MF); both primary and those arising from an antecedent polycythemia vera (PV) and essential thrombocythemia (ET) . We report here the overall efficacy of three different thalidomide-prednisone based regimens (alone or in combination with either oral cyclophosphamide for three months or continuous weekly etanercept) when assessed by the IWG-MRT response criteria  which were developed after completion of these studies. Additionally we report on the durability of response and long-term follow-up. We observed an overall response rate of 28% by IWG-MRT criteria (mostly clinical improvement—22% anemia, 8% splenomegaly) with a median duration of response of 8.5 months. Toxicities primarily consisted of neuropathy (Grade 3 or higher neuropathy in 6%) and cytopenias (Grade 3 or higher in 20%). After a median follow-up of three years, fourteen patients (28%) had expired from MF at the time of this analysis with median survival of 36 months.
MF is a chronic, clonal myeloproliferative neoplasm characterized by progressive anemia, leukoerythroblastic peripheral blood smear picture, splenomegaly and the potential transformation to acute leukemia . Clinically, patients experience a heterogeneous course with problems of significant constitutional symptoms , progressive anemia, and splenomegaly. The treatment of patients with MF remains unsatisfactory. Allogeneic stem cell transplantation is a potentially curative option , but its wide applicability is limited by significant toxicity, lack of suitable donors, and the advanced age of many MF patients. Currently available medical therapies have been only of modest efficacy and used mainly for palliation of MF-associated cytopenias (erythropoietin , androgens like danazol [7, 8]) or splenomegaly (hydroxyurea , interferon ). Median survival of patients with MF has not improved with medical therapy.
Thalidomide, originally developed as a sedative, hypnotic agent in the 1950s exhibits potent anti-angiogenic properties by inhibiting basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) [11, 12]. Initial tests of thalidomide in MF [13, 14] demonstrated improvement in cytopenias without much impact on splenomegaly, and none on the histologic manifestations of the disease. Tolerance at doses in excess of 100 mg/day was poor (100–800 mg) with significant neurotoxicity which was dose limiting. We performed a subsequent Phase 2 study demonstrating that low dose thalidomide (50 mg) with a tapering dose of prednisone had a much better tolerance with improvement in cytopenias with modest efficacy for splenomegaly . Among objective responses based upon the criteria of that trial 62% of patients experienced improvement in anemia, 40% achieved transfusion independence and 19% had a reduction in their spleen size.
Subsequently we tried to augment the efficacy seen with thalidomide-prednisone by the addition of low dose oral cyclophosphamide (as there was some evidence of synergy when it was used with thalidomide and steroids in multiple myeloma ). Additionally, a second combination trial of thalidomide-prednisone with the TNF-alpha inhibitor etanercept (demonstrated single agent symptomatic benefit ) was undertaken. In this report we assess the combined long term follow-up on our three thalidomide-prednisone based clinical trials. Finally, we analyzed the outcomes from Thal-pred based MF therapy in light of the IWG-MRT prognostic and response criteria both of which were developed subsequent to these trials [2, 17].
A total of 50 patients with MF were enrolled between the three trials (See Table I for demographic information) with demographic characteristics typical for the disorder. Median age at enrollment was 68 years (range, 46–85 years) and 14 were females (28%). Thirty-four (68%) had PMF and the remainder had evolved from pre-existing PV and ET. Forty-five (90%) had Intermediate-2 or higher risk disease by IWG-MRT prognostic criteria. Thirty-one patients were transfusion-dependent prior to the study (62%). The median spleen size was 17.2 cm (range, 0–34 cm). Overall, 78% patients reached the three month juncture on the trials (at which point prednisone was stopped), with 40% reaching six months. Ninety-five percent patients were able to complete the first three months of treatment with thalidomide-prednisone alone whereas it dropped to 73% and 57% for thalidomide-prednisone-etanercept and thalidomide-prednisone-cyclophosphamide, respectively.
|Demographics||TPC (N = 14)||TPE (N = 15)||TP (N = 21)||Totals (N = 50)|
|Median age (years)||72.5 (range 46–85)||67 (54–78)||65 (43–78)||68 (43–85)|
|Sex||M - 7 (50%)||M −13 (86%)||M −16 (76%)||M-36 (72%)|
|Type of MF||Primary −11 (79%)||9 (60%)||14 (67%)||34 (68%)|
|Post-PV-3 (21%)||2 (13%)||2 (9%)||7 (14%)|
|Post-ET-0||4 (27%)||5 (24%)||9 (18%)|
|IWG-MRT prognostic group ||Low-0||0||1 (5%)||1 (2%)|
|Intermediate1–1 (7%)||1 (7%)||2 (9%)||4 (8%)|
|Intermediate2–1 (7%)||7 (47%)||8 (38%)||16 (32%)|
|High risk-12 (86%)||7 (47%)||10 (48%)||29 (58%)|
|Performance Status (ECOG)|
|Transfusion dependent anemiaa||8/14 (57%)||7/15 (47%)||16/21 (76%)||31 (62%)|
|Median platelets (×10 9/L)||76 (11–229)||127 (9–512)||154 (23–448)||117 (11–512)|
|Median WBC (×10 9/L)||11(2.8–70.1)||8.15 (2.6–116)||9.6 (1.6–23.5)||11 (1.6–116)|
|Abnormal karyotype at enrollment||5/14 (35%)||8/15 (53%)||12/21 (57%)||25 (50%)|
|Median spleen sizeb||17.2 (0–29)||19.7 (0–23)||16.8 (0–34)||17.2 (0–34)|
In general across the trials there was good tolerance except for the thalidomide-prednisone-cyclophosphamide regimen (Table II). Toxicity during active therapy included myelosuppression with three cases of Grade 3 anemia, three cases of Grade 3 neutropenia, and four cases of Grade 3 thrombocytopenia (mostly in the cyclophosphamide containing regimen). Initial neuropathy was uncommon with only three cases of Grade 3 neuropathy observed. There was no treatment-attributable mortality. When responses were assessed BY IWG-MRT criteria , none of the patients were able to achieve complete response (CR) and there was only one partial remission (PR). Fourteen (28%) obtained clinical improvement (CI) by the IWG-MRT response assessment criteria and the majority (48%) of responses were stable disease (SD). Among the achievers of CI, 11 had response for anemia (22%) and 4 (8%) had response for splenomegaly (one patient in Thalidomide-Prednisone regimen had combined response to anemia and splenomegaly).
|Toxicity||TPC (N = 14)||PET (N = 15)||TP (N = 16)||Totals (N = 50)|
|Toxicity observed (≥ Grade 3)|
|Efficacy and outcomes|
|Median duration of follow up (Months)||22.5 (3–57)||58 (6–75)||42 (6–106)||36 (3–106)|
|Completion of 3 cycles||8/14 (57%)||11/15 (73%)||20/21 (95%)||39 (78%)|
|Reason for stopping therapy||No response (N = 7)||(N = 8)||(N = 8)||23 (46%)|
|Toxicity (N = 4)||(N =1)||(N = 2)||7 (14%)|
|Response by IWG criteria |
|Median time to response (weeks)||4||4||8||8|
|Median duration of response (months)||6 (only one response)||9.5 (6–16)||8 (3–42)||7 (3–42)|
|Median time to next therapy (months)||2 (1–4)||3 (1–45)||7 (2–50)||3 (1–50)|
After a median follow up of 36 months across this cohort, we observed an overall median duration of response of 8.5 months (range, 3–42 months). Median time to institution of next therapy was three months (range, 1–50 months). There were patients with periods of prolonged stabilization after cessation of therapy. At the time of this analysis, 14 patients (28%) had expired from MF. Median survival across the entire cohort was 36 months (range, 3–106).
Although comparison of three independent trials is not an ideal way to compare and contrast regimen effectiveness, this report suggests greater toxicity, inferior response rate, duration of response, and time to next therapy with the cyclophosphamide containing regimen. There were more females in the regimen containing cyclophosphamide than the other two. More patients had transfusion dependent anemia in the thalidomide-prednisone alone regimen whereas more patients were thrombocytopenic in the cyclophosphamide containing regimen. The median spleen size was comparable across the three studies but more patients had less chromosomal abnormalities in the cyclophosphamide containing. Eastern cooperative group (ECOG) performance status was comparable among these three studies but significantly higher percentage of patients turned out to be high risk by the new IWG-MRT risk assessment criteria in the cyclophosphamide and etanercept containing studies. Despite reported synergy of cyclophosphamide in multiple myeloma and activity of etanercept in alleviating constitutional symptoms in MF, addition of these agents to thalidomide and prednisone does not seem to augment the efficacy. This could partly be secondary to inability of patients to complete the planned total duration of treatment due to toxicity and intolerance. It could also be secondary to more patients belonging to a higher risk prognostic category (as suggested by IWG-MRT criteria) in the other two regimens. Nevertheless, thalidomide-prednisone based regimens seem to be active in a subset of patients with MF, with modest response rates by IWG-MRT criteria but limited by neuropathy.
The therapeutic landscape in MF is changing fast. The discovery of JAK2-V617F mutation, and other molecular insights into the pathophysiology of myeloproliferative neoplasms, has opened an era of potential new therapies for MF. Over a dozen JAK2 inhibitors are in development . Epigenetic changes are being targeted with agents like decitabine [19, 20]. Reduced intensity allogeneic transplantation is being explored which may broaden its applicability to more patients with curative potential [21, 22]. Newer Jak-2 inhibitors seem to have their main effect on splenomegaly with potential worsening of cytopenias [23, 24]. Pomalidomide, a distinct IMiD® immunomodulatory drug, is being tested in MF [25, 26]. Published response rates of pomalidomide appear equal or exceed that of thalidomide-prednisone based regimens without treatment limiting neuropathy.
Methods and Study Design
The patients were enrolled in all the three studies after approval from the Mayo Clinic Institutional Review Board. We retrospectively analyzed the data taking into account IWG-MRT response and prognostic criteria. Patients with primary MF and those with MF secondary to Polycythemia Vera (PV) and Essential Thrombocythemia (ET) were eligible. All patients had a pretreatment physical examination, baseline laboratory assessment, assessment of circulatory hematological parameters and bone marrow examination with cytogenetics and fluorescent in situ hybridization (FISH) to exclude occult chronic myelogenous leukemia. Thalidomide was administered per the Celgene System for Thalidomide Education and Prescribing Safety (STEPS) program. In the thalidomide-prednisone study; patients received thalidomide 50-mg orally daily. Prednisone was given in a tapering fashion; 0.5 mg/kg/d for first month, 0.25 mg/kg/d for second month, and 0.125 mg/kg/d for the third month. Patients continued to receive additional three months of thalidomide at the 50 mg daily dose if they showed any response for cytopenias and organomegaly. In the thalidomide-prednisone-cyclophosphamide study; patients received oral cyclophosphamide 25 mg daily for three months along with thalidomide 50 mg daily and prednisone taper as before. Thalidomide was continued as maintenance treatment if there was a response. In the thalidomide-prednisone-etanercept study; 25 mg dose of etanercept was administered subcutaneously twice-a-week along with thalidomide-prednisone as in the aforementioned studies. Patients remained on etanercept and thalidomide if they had any response per protocol. The National Cancer Institute Common Toxicity Criteria (NCI CTC versions 3.0) was used to evaluate toxicity. The descriptive statistics were calculated using means, standard deviations, medians, and ranges for continuous variables; frequencies and relative frequencies for categorical variables. The survival was calculated using Kaplan-Meier survival statistics. 1
- 1Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 2007; 31: 737–740., , , et al.
- 2International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006; 108: 1497–1503., , , et al.
- 3Myelofibrosis with myeloid metaplasia. New England Journal of Medicine 2000; 342: 1255–1265..
- 4The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 2009; 33: 1199–1203., , , et al.
- 5Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999; 93: 2831–2838., , , et al.
- 6Recombinant human erythropoietin for the treatment of anemia in myelofibrosis with myeloid metaplasia [letter]. Am J Hematol 1995; 48: 135–136., , , .
- 7Danazol treatment of idiopathic myelofibrosis with severe anemia. Haematologica 2000; 85: 595–599., , , , .
- 8Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in prediciting response and survival. Cancer 1982; 49: 308., , , .
- 9Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. European Journal of Haematology 1988; 41: 375–381., .
- 10Alpha interferon treatment of idiopathic myelofibrosis. Med Clin (Barc) 1993; 101: 498–500., , , , .
- 11Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America 1994; 91: 4082–4085., , , .
- 12Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Experimental Eye Research 1997; 64: 971–978., , .
- 13Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2001; 114: 78–83., , , , , .
- 14Thalidomide in agnogenic and secondary myelofibrosis. Br J Haematol 2001; 115: 313–315., , , et al.
- 15A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003; 101: 2534–2541., , , et al.
- 16The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 2004; 18: 856–863., , , et al.
- 17Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study. Blood 2002; 99: 2252–2254., , , , .
- 18New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895–2901., , , et al.
- 19How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood 2009; 113: 5394–5400..
- 20Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives. J Cell Mol Med 2009; 13: 1437–1450., , , , .
- 21Decitabine is an effective treatment of idiopathic myelofibrosis. Br J Haematol 2009; 145: 131–132., , , .
- 22Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis. Biol Blood Marrow Transplant 2006; 16: 281–286., , , et al.
- 23Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009; 114: 5264–5270., , , et al.
- 24Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. New England Journal of Medicine 2010; 363: 1117–1127., , , et al.
- 25Phase1/-2 study of Pomalidomide in myelofibrosis. Am J Hematol 2010; 85: 129–130., , , et al.
- 26Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009; 27: 4563–4569., , , et al.
Prakash Thapaliya*, Ayalew Tefferi, Animesh Pardanani, David P. Steensma, John Camoriano*, Wenting Wu§, Susan Geyer¶, Ruben A. Mesa*, * Division of Hematology/Oncology, Mayo Clinic Scottsdale, Arizona, Division of Hematology, Mayo Clinic Rochester, Minnesota, Dana-Farber Cancer Institute, Wellesley, Massachusetts, § Department of Biostatistics, Mayo Clinic Rochester, ¶ Department of Biostatistics, Ohio State University.